These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12797485)

  • 1. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis.
    Polzin A; Pletz M; Erbes R; Raffenberg M; Mauch H; Wagner S; Arndt G; Lode H
    Eur Respir J; 2003 Jun; 21(6):939-43. PubMed ID: 12797485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia.
    Schleicher GK; Herbert V; Brink A; Martin S; Maraj R; Galpin JS; Feldman C
    Eur Respir J; 2005 Apr; 25(4):688-92. PubMed ID: 15802344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic value of serum procalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosis.
    Niu WY; Wan YG; Li MY; Wu ZX; Zhang LG; Wang JX
    Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3329-33. PubMed ID: 24379064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia.
    Kang YA; Kwon SY; Yoon HI; Lee JH; Lee CT
    Korean J Intern Med; 2009 Dec; 24(4):337-42. PubMed ID: 19949732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum procalcitonin level: clinical significance.
    Aggarwal D; Mohapatra PR; Aggarwal P
    Eur Respir J; 2011 Mar; 37(3):723; author reply 723. PubMed ID: 21357930
    [No Abstract]   [Full Text] [Related]  

  • 6. C-reactive protein, procalcitonin, clinical pulmonary infection score, and pneumonia severity scores in nursing home acquired pneumonia.
    Porfyridis I; Georgiadis G; Vogazianos P; Mitis G; Georgiou A
    Respir Care; 2014 Apr; 59(4):574-81. PubMed ID: 24106319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of serum procalcitonin levels in pulmonary tuberculosis.
    Ugajin M; Miwa S; Shirai M; Ohba H; Eifuku T; Nakamura H; Suda T; Hayakawa H; Chida K
    Eur Respir J; 2011 Feb; 37(2):371-5. PubMed ID: 20530033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection.
    Ingram PR; Inglis T; Moxon D; Speers D
    Intensive Care Med; 2010 Mar; 36(3):528-32. PubMed ID: 20069274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
    Ugajin M; Yamaki K; Hirasawa N; Yagi T
    Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.
    Jereb M; Kotar T
    Wien Klin Wochenschr; 2006 Apr; 118(5-6):170-4. PubMed ID: 16773483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis.
    Hoshina T; Nanishi E; Kanno S; Nishio H; Kusuhara K; Hara T
    J Infect Chemother; 2014 Oct; 20(10):616-20. PubMed ID: 25027057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
    Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
    J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.
    Christ-Crain M; Jaccard-Stolz D; Bingisser R; Gencay MM; Huber PR; Tamm M; Müller B
    Lancet; 2004 Feb; 363(9409):600-7. PubMed ID: 14987884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
    Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
    Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of serum procalcitonin and high-sensitivity C-reactive protein with pneumonia in elderly multimorbid patients with respiratory symptoms: retrospective cohort study.
    Nouvenne A; Ticinesi A; Folesani G; Cerundolo N; Prati B; Morelli I; Guida L; Lauretani F; Maggio M; Aloe R; Lippi G; Meschi T
    BMC Geriatr; 2016 Jan; 16():16. PubMed ID: 26772604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.
    Bafadhel M; Clark TW; Reid C; Medina MJ; Batham S; Barer MR; Nicholson KG; Brightling CE
    Chest; 2011 Jun; 139(6):1410-1418. PubMed ID: 21030489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of serum procalcitonin in patients with community-acquired lobar pneumonia.
    Lee JY; Hwang SJ; Shim JW; Jung HL; Park MS; Woo HY; Shim JY
    Korean J Lab Med; 2010 Aug; 30(4):406-13. PubMed ID: 20805714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procalcitonin and severity of community-acquired pneumonia.
    Okimoto N; Hayashi Y; Ishiga M; Nanba F; Kishimoto M; Yagi S; Kurihara T; Asaoka N; Tamada S
    J Infect Chemother; 2009 Dec; 15(6):426-7. PubMed ID: 20012738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum procalcitonin and respiratory tract infections].
    Zarka V; Valat C; Lemarié E; Boissinot E; Carré P; Besnard JC; Diot P
    Rev Pneumol Clin; 1999 Dec; 55(6):365-9. PubMed ID: 10685471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.